Specific adverse events:nervous system disorder · adults with chronic neuropathic pain
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
Mirtazapine showed no clear difference in tolerability: withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
The intervention may leads to lower adverse events ‐ Overt hepatic encephalopathy ( (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Overt hepatic encephalopathy ( · people with hepatic encephalopathy
It is very uncertain whether the intervention changes adverse events ‐ Overt hepatic encephalopathy ( (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether laser ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of participants) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with cervical dystonia
Botulinum neurotoxin B showed no clear difference in proportion of withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: Acupuncture versus no treatment · women with primary dysmenorrhoea
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at post‐treatment ‐ not reported · adults with anxiety disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events post‐intervention ‐ not reported · patients with fibromyalgia
The review found no eligible studies for this question.
1 finding from 1 review
All topical NSAIDs Withdrawals ‐ adverse events · adults with strains, sprains, or muscle pull
1 finding from 1 review
In‐hospital adverse events; postoperative fever · women with uterine fibroids
Laparoscopic myomectomy probably leads to lower in‐hospital adverse events; postoperative fever compared with open myomectomy (all types) (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with DPN
Alpha‐lipoic acid showed no clear difference in adverse events leading to cessation of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review